122. (Amended) A compound having the structure:

or its enantiomer,

or a pharmaceutically acceptable salt, prodrug or derivative thereof.

As a courtesy to the Examiner, enclosed please find a marked up and clean copy of the specification (amended pages only) and the amended claim.

If a telephone interview would advance prosecution of the subject application, the Examiner is invited to telephone the undersigned at the number provided below. In the unlikely event that the transmittal letter is separated from this document and/or the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such

petitions and/or other fees due in connection with the filing of this document to **Deposit Account**No. 50-0974, referencing attorney's docket no. 128019-203801. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Antoinette F. Konski (Reg. No. 34,202)

Date: January 9, 2001

Baker & McKenzie 660 Hansen Way

Palo Alto, California 94304 Telephone: (650) 856-2400 Facsimile: (650) 856-9299

> Application Serial No. 09/700,101 Attorney's Docket No.: 128019-203801

3